Congenital Complete Atrioventricular Heart Block in a Pregnant Woman with Sjögren Syndrome: Prenatal Care Follow-Up and the Challenge of Intrauterine Treatment.
Milene Carvalho CarrilhoNathalie Jeanne Magioli Bravo-ValenzuelaAntonio Fernandes MoronPublished in: Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia (2020)
The present report describes a case of complete atrioventricular block (CAVB) diagnosed at 25 weeks of gestation in a pregnant woman with Sjögren's syndrome and positive anti-Ro/SSA antibodies. Fluorinated steroids (dexamethasone and betamethasone) and terbuline were used to increase the fetal heart rate, but the fetal heart block was not reversible, and the administration of drugs was discontinued due to maternal collateral effects. Follow-up fetal echocardiograms were performed, and the fetus evolved with pericardial effusion, presence of fibroelastosis in the right ventricle, and ventricular dysfunction. Interruption of pregnancy by cesarean section was indicated at 34 weeks of gestation, and a cardiac pacemaker was implanted in the male newborn immediately after birth. Therapy for fetuses with CAVB is controversial mainly regarding the use or not of corticosteroids; however, monitoring of the atrioventricular interval by fetal echocardiography should be performed in fetuses from pregnant women with positive autoantibodies anti-Ro/SSA and/or anti-La/SSB to prevent the progression to CAVB.
Keyphrases
- gestational age
- birth weight
- heart rate
- preterm birth
- pregnant women
- left ventricular
- heart failure
- case report
- catheter ablation
- heart rate variability
- pregnancy outcomes
- atrial fibrillation
- healthcare
- blood pressure
- preterm infants
- pulmonary hypertension
- disease activity
- systemic lupus erythematosus
- computed tomography
- oxidative stress
- mitral valve
- high dose
- body mass index
- quality improvement
- rheumatoid arthritis
- congenital heart disease
- pulmonary artery
- drug induced
- health insurance
- inferior vena cava
- replacement therapy